Diestelhorst M, Hinzpeter B, Krieglstein G K
University Eye Clinic Cologne, Germany.
Int Ophthalmol. 1991 Jul;15(4):259-62. doi: 10.1007/BF00171028.
In a randomized, double-masked, single drop study the effect of topical isosorbid-mononitrate (ISMO) 0.5% eye drops, the main metabolite of isosorbid-dinitrate, widely used in the treatment of coronary heart diseases, was studied in patients suffering from open angle glaucoma or ocular hypertension. There was no statistically significant IOP change within 8 hours posttreatment after topical administration of ISMO 0.5%. There were no side effects after application of the ophthalmic solution of ISMO 0.5%. There were no significant changes in blood pressure and pulse rate either. A 2% ophthalmic solution of ISMO was investigated with respect to a response on the aqueous humor dynamics in 10 healthy volunteers. Anterior chamber fluorophotometry revealed a mean increase in aqueous flow of 39% within 3 hours after topical application (P less than 0.01). However, in comparison to the placebo treated fellow eyes there were no statistical significant difference in aqueous humor flow during the time of investigation. There was a statistical significant reduction of IOP during the same time period (p less than 0.03) in all treated eyes.
在一项随机、双盲、单剂量研究中,对患有开角型青光眼或高眼压症的患者,研究了硝酸异山梨酯(ISMO)0.5%滴眼液(硝酸异山梨酯的主要代谢产物,广泛用于治疗冠心病)的效果。局部应用ISMO 0.5%后8小时内,眼压无统计学显著变化。应用0.5% ISMO眼用溶液后无副作用。血压和脉搏率也无显著变化。对10名健康志愿者研究了2% ISMO眼用溶液对房水动力学的反应。前房荧光光度法显示局部应用后3小时内房水流量平均增加39%(P<0.01)。然而,与安慰剂治疗的对侧眼相比,在研究期间房水流量无统计学显著差异。所有治疗眼在同一时间段内眼压有统计学显著降低(P<0.03)。